다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Molecular therapy : the journal of the American Society of Gene Therapy, v.6 no.3, 2002년, pp.342 - 348
Vlachaki, Maria T (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Hernandez-Garcia, Andres (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Ittmann, Michael (Department of Pathology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Chhikara, Madhu (Advantagene, Inc. San Diego, California, 92126, USA) , Aguilar, Laura K (Harvard Gene Therapy Initiative, Harvard Medical School, Boston, Massachussets, 02115, USA) , Zhu, Xiaohong (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , The, Bin S (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Butler, E.Brian (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Woo, Shiao (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Thompson, Timothy C (Department of Radiology, Baylor College of Medicine, Houston, Texas, 77030, USA) , Barrera-Saldana, Hugo (Department of Biochemistry, Medical School, University of Nuevo Leon, Nuevo Leon, Mexico) , Aguilar-Cordova, Estuardo (Harvard Gene Therapy Initiative, Harvard Medical School, Boston, Massachussets, 02115, USA)
AI-Helper
AbstractImmune responses against adenoviral vectors may influence the toxicity and therapeutic effectiveness of adenovirus-mediated gene transfer and may be a limiting factor in adenovirus-mediated gene therapy. The purpose of this study was to determine the effects of preimmunization on intratumora...
Horwitz, M. S.1996. Adenoviruses. In Fields VirologyB. Fields, D. M. Knipe, and P. M. Howley, Eds., pp. 2149-2171. Lippincott, Philadelphia.
Adv. Drug Deliv. Rev. Trapnell 12 185 1993 10.1016/0169-409X(93)90059-D Adenoviral vectors for gene transfer
Gene Ther. Cichon 8 1794 2001 10.1038/sj.gt.3301611 Complement activation by recombinant adenoviruses
Hum. Gene Ther. Raper 13 163 2002 10.1089/10430340152712719 A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency
Hum. Gene Ther. Herman 10 1239 1999 10.1089/10430349950018229 In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial
Int. J. Radiat. Oncol. Biol. Phys. Vlachaki 51 1008 2001 10.1016/S0360-3016(01)01698-4 Enhanced therapeutic effect of multiple injections of HSV-TK+GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model
Int. J. Radiat. Oncol. Biol. Phys. Teh 51 605 2001 10.1016/S0360-3016(01)01692-3 Phase I-II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report
Hum. Gene Ther. Miles 12 1955 2001 10.1089/104303401753204535 Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer therapy failing radiotherapy
Hum. Gene Ther. Morral 8 1275 1997 10.1089/hum.1997.8.10-1275 Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors
Gene Ther. Bramson 4 1069 1997 10.1038/sj.gt.3300508 Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
Hum. Gene Ther. Morral 13 143 2002 10.1089/10430340152712692 Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons
Hum. Gene Ther. Molnar-Kimber 9 2121 1998 10.1089/hum.1998.9.14-2121 Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
Oncol. Res. Thompson 11 1 1999 In situ gene therapy for prostate cancer
J. Urol. Shalev 163 1747 2000 10.1016/S0022-5347(05)67534-9 Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
Gene Ther. Yang 3 412 1996 Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver
Lab. Invest. Sun 63 467 1990 Two rat models of hepatic fibrosis. a morphologic and molecular comparison
J. Virol. Clabough 65 6242 1991 10.1128/JVI.65.11.6242-6251.1991 Immune-mediated thrombocytopenia in horses infected with equine infectious anemia virus
Clin. Exp. Immunol. Lurhuma 28 49 1977 The occurrence of circulating immune complexes and viral antigens in idiopathic thrombocytopenic purpura
Hum. Gene Ther. 13 3 2002 10.1089/10430340152712629
Proc. Natl. Acad. Sci. USA Morral 96 12816 1999 10.1073/pnas.96.22.12816 Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
Hum. Gene Ther. Lanuti 10 463 1999 10.1089/10430349950018904 Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy
Hum. Gene Ther. Fang 6 1039 1995 10.1089/hum.1995.6.8-1039 Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression
Eur. J. Immunol. Ludviksson 30 2011 2000 10.1002/1521-4141(200007)30:7<2101::AID-IMMU2101>3.0.CO;2-P The effect of TGF-β1 on immune responses of naive versus memory CD4+ Th1/Th2 T cells
Nat. Med. Nyberg-Hoffman 3 808 1997 10.1038/nm0797-808 Sensitivity and reproducibility in adenoviral infectious titer determination
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.